Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-21527.81%
operating margin TTM
-34718.6%
revenue TTM
101.96 Million
revenue per share TTM
0.49$
valuation ratios | |
|---|---|
| pe ratio | -0.22 |
| peg ratio | -0.00 |
| price to book ratio | -0.95 |
| price to sales ratio | 1,074.29 |
| enterprise value multiple | -4.09 |
| price fair value | -0.95 |
profitability ratios | |
|---|---|
| gross profit margin | 90.7% |
| operating profit margin | -34718.6% |
| pretax profit margin | -34695.35% |
| net profit margin | -21527.81% |
| return on assets | -226.11% |
| return on equity | 851.02% |
| return on capital employed | 686.71% |
liquidity ratio | |
|---|---|
| current ratio | 0.59 |
| quick ratio | 0.59 |
| cash ratio | 0.50 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 2,011.74 |
| days of payables outstanding | 419,658.75 |
| cash conversion cycle | -417,647.01 |
| receivables turnover | 0.18 |
| payables turnover | 0.00 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.00 |
| debt equity ratio | 0.00 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.00 |
| interest coverage | -533.18 |
| cash flow to debt ratio | 0.00 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.86 |
| cash per share | 0.34 |
| operating cash flow per share | -0.86 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | 0.00 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | 0.00 |
Frequently Asked Questions
When was the last time Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) reported earnings?
Cyclacel Pharmaceuticals, Inc. (CYCC) published its most recent earnings results on 12-11-2024.
What is Cyclacel Pharmaceuticals, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC)'s trailing twelve months ROE is 851.02%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Cyclacel Pharmaceuticals, Inc. (CYCC) currently has a ROA of -226.11%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did CYCC's net profit margin stand at?
CYCC reported a profit margin of -21527.81% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is CYCC's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 0.59 in the most recent quarter. The quick ratio stood at 0.59, with a Debt/Eq ratio of 0.00.